KOL Views: Setting expectations for Bayer, Merck & Co.’s vericiguat based on top-line HFrEF win

Bayer and Merck & Co. revealed top-line Phase III VICTORIA results this week showing that vericiguat reduced cardiovascular events versus placebo in patients with worsening heart failure (HF) with reduced ejection fraction (HFrEF) when added to standard of care. Additional details about the soluble guanylate cyclase (sGC) stimulator’s performance will be presented at a medical conference in 2020.

To provide FirstWord readers with rapid feedback on how and where vericiguat could impact HF prescribing patterns, we are hosting an expert call with a key opinion leader (KOL) later this week.

Key topics that will be discussed during the call include, among other things… how surprised are you by vericiguat’s significant improvement on HF hospitalisation and cardiovascular death; analysts have theorised that a 15% to 20% reduction on the composite endpoint is needed to change prescribing patterns – would you agree with this benchmark; is a significant benefit in the subgroup of patients also receiving Novartis’ Entresto (sacubitril/valsartan) needed to drive real world use; is it important for vericiguat to have an impact on cardiovascular death and not just HF hospitalisation; how optimistic are you that vericiguat will change prescribing patterns in HFrEF; will the availability of SGLT2 inhibitors for treating HF have any impact on use of vericiguat; does vericiguat’s top-line success in HFrEF change your perception of sGC stimulators; how optimistic are you that vericiguat will work in HFpEF and do top-line VICTORIA results increase your level of confidence?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving HF treatment algorithm.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.